Immix Biopharma Inc

NASDAQ IMMX

Data sourced from

and

Download Data

Immix Biopharma Inc Net Operating Profit After Tax (NOPAT) 5 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024

Immix Biopharma Inc Net Operating Profit After Tax (NOPAT) 5 year CAGR is NA for the Trailing 12 Months (TTM) ending March 31, 2024. Net Operating Profit After Taxes (NOPAT) is a financial metric that represents a company's operating profit after deducting taxes. It is calculated by multiplying the earnings before interest and taxes (EBIT) by (1 - tax rate). NOPAT provides insights into the company's profitability from its core operations while accounting for the impact of taxes. It is useful for assessing the company's operating performance and comparing profitability across different tax environments. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Immix Biopharma Inc Net Operating Profit After Tax (NOPAT) for the Trailing 12 Months (TTM) ending March 31, 2023 was -2,348,391.25, a -272.50% change year over year.
Immix Biopharma Inc Net Operating Profit After Tax (NOPAT) for the Trailing 12 Months (TTM) ending March 31, 2022 was -630,437.73, a -90.26% change year over year.
Immix Biopharma Inc Net Operating Profit After Tax (NOPAT) for the Trailing 12 Months (TTM) ending March 31, 2021 was -331,356.23.

NASDAQ: IMMX

Immix Biopharma Inc

CEO	Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
IPO Date	Dec. 16, 2021
Location	United States
Headquarters	11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064
Employees	14
Sector	Healthcare
Industry	Biotechnology

Description

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Key trends